TD Cowen analyst Tyler Van Buren raised the firm’s price target on Travere Therapeutics (TVTX) to $40 from $30 and keeps a Buy rating on the shares. The firm said Q3 Filspari sales of $91MM (+26% Q/Q) led to an impressive 15% beat over consensus, underscoring strong demand, PSF pull-through, and persistence.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TVTX:
- Buy Rating Affirmed: Travere Therapeutics Surpasses Expectations with Strong Financial Performance and Strategic Milestones
- Travere Therapeutics Reports Strong Q3 2025 Growth
- Strong Buy Recommendation for Travere Therapeutics: Impressive Sales Growth and Strategic Positioning Highlight Future Potential
- Closing Bell Movers: Amazon soars to all-time highs on earnings
- Travere Therapeutics reports Q3 EPS 29c, consensus (9c)